dadstimeon Posted January 10, 2007 Share Posted January 10, 2007 http://today.reuters.com/news/articlein ... &type=qcna Jan 9 (Reuters) - Introgen Therapeutics Inc. (INGN.O: Quote, Profile , Research) said a preclinical study showed that its cancer therapy INGN 241 causes human lung cancer cells to undergo cell death. Shares of the biopharmaceutical company rose more than 5 percent to $4.88 in afternoon trade on the Nasdaq. Introgen said the study showed that the combination of INGN 241 and two heat shock protein 90 (Hsp90) inhibitors, a new class of tumor-targeted drugs, resulted in enhancement of lung cancer cell death. The study was conducted by researchers from the University of Texas M. D. Anderson Cancer Center, in collaboration with Introgen scientists, the company said in a statement. Introgen said the combination treatment offers promise for improving efficacy using low-toxicity drugs for lung cancer. INGN 241 is currently being evaluated for various cancers. (Reporting by Varsha Tickoo in Bangalore) Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.